229 related articles for article (PubMed ID: 17365170)
21. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
Robinson DS; Amsterdam JD
J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687
[TBL] [Abstract][Full Text] [Related]
22. Transdermal selegiline in patients receiving electroconvulsive therapy.
Horn PJ; Reti I; Jayaram G
Psychosomatics; 2010; 51(2):176-8. PubMed ID: 20332294
[TBL] [Abstract][Full Text] [Related]
23. Selegiline transdermal system in major depressive disorder: profile report.
Frampton JE; Plosker GL
CNS Drugs; 2007; 21(6):521-4. PubMed ID: 17521230
[No Abstract] [Full Text] [Related]
24. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).
Jang S; Jung S; Pae C; Kimberly BP; Craig Nelson J; Patkar AA
J Affect Disord; 2013 Dec; 151(3):854-9. PubMed ID: 24021959
[TBL] [Abstract][Full Text] [Related]
25. Transdermal selegiline: a novel MAOI formulation for depression.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2006 Jul; 44(7):9-12. PubMed ID: 17310829
[No Abstract] [Full Text] [Related]
26. Transdermal selegiline.
Patkar AA; Pae CU; Zarzar M
Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
[TBL] [Abstract][Full Text] [Related]
27. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
Amsterdam JD
J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
[TBL] [Abstract][Full Text] [Related]
28. Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications.
Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
J Clin Pharmacol; 2007 Feb; 47(2):146-58. PubMed ID: 17244765
[TBL] [Abstract][Full Text] [Related]
29. Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression.
Tulen JH; Volkers AC; van den Broek WW; Bruijn JA
J Clin Psychopharmacol; 2006 Oct; 26(5):542-4. PubMed ID: 16974207
[No Abstract] [Full Text] [Related]
30. Monoamine oxidase inhibitors: a new generation.
Robinson DS
Psychopharmacol Bull; 2002; 36(3):124-38. PubMed ID: 12473970
[TBL] [Abstract][Full Text] [Related]
31. Discussion: a fresh look at monoamine oxidase inhibitors for depression.
Cohen LJ; Sclar DA; Culpepper L; Flockhart DA; Hirschfeld RM; Thase ME; VanDenBerg CM
J Clin Psychiatry; 2012; 73 Suppl 1():42-5. PubMed ID: 22951242
[No Abstract] [Full Text] [Related]
32. MAOIs and transdermal delivery.
Vandenberg CM
J Clin Psychiatry; 2012 Sep; 73(9):e28. PubMed ID: 23059160
[TBL] [Abstract][Full Text] [Related]
33. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.
Clayton AH; Campbell BJ; Favit A; Yang Y; Moonsammy G; Piontek CM; Amsterdam JD
J Clin Psychiatry; 2007 Dec; 68(12):1860-6. PubMed ID: 18162016
[TBL] [Abstract][Full Text] [Related]
34. Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction on tyramine.
Preskorn SH
J Psychiatr Pract; 2006 May; 12(3):168-72. PubMed ID: 16732136
[No Abstract] [Full Text] [Related]
35. Treatment-resistant depression: response to low-dose transdermal but not oral selegiline.
Morgan PT
J Clin Psychopharmacol; 2007 Jun; 27(3):313-4. PubMed ID: 17502787
[No Abstract] [Full Text] [Related]
36. Selegiline transdermal system: current awareness and promise.
Pae CU; Lim HK; Han C; Neena A; Lee C; Patkar AA
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1153-63. PubMed ID: 17614182
[TBL] [Abstract][Full Text] [Related]
37. The use of monoamine oxidase inhibitors in primary care.
Culpepper L
J Clin Psychiatry; 2012; 73 Suppl 1():37-41. PubMed ID: 22951241
[TBL] [Abstract][Full Text] [Related]
38. What is the bottom line for dietary guidelines when taking monoamine oxidase inhibitors?
Marcason W
J Am Diet Assoc; 2005 Jan; 105(1):163. PubMed ID: 15635366
[No Abstract] [Full Text] [Related]
39. Selegiline transdermal system: in the treatment of major depressive disorder.
Frampton JE; Plosker GL
Drugs; 2007; 67(2):257-65; discussion 266-7. PubMed ID: 17284087
[TBL] [Abstract][Full Text] [Related]
40. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
